Champions Oncology, Inc.

Champions Oncology, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Champions Oncology, Inc. is not very popular among insiders. Champions Oncology, Inc. is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to...
CSBR Fundamental Data by TradingView

News

Champions Oncology upgraded to buy by Craig-Hallum
Champions Oncology upgraded to buy by Craig-Hallum

SeekingAlpha.com: All News Craig-Hallum upgraded Champions Oncology (CSBR) to buy, commenting that it sees the CRO returning to revenue predictability over the next couple of quarters. Read more here.\n more…

Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript

SeekingAlpha Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript...\n more…

Champions Oncology reports Q1 EPS 11c vs. (16c) last year
Champions Oncology reports Q1 EPS 11c vs. (16c) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

Accesswire HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions...\n more…

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

Accesswire HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...\n more…

Champions Oncology (NASDAQ:CSBR investor three-year losses grow to 58% as the stock sheds US$8.0m this past week
Champions Oncology (NASDAQ:CSBR investor three-year losses grow to 58% as the stock sheds US$8.0m this past week

Simply Wall St Research Champions Oncology's (Nasdaq:CSBR) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.\n more…